

AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A temperature-sensitive, host-range restricted mutant flavivirus, designated mutant 200, 201, wherein said virus comprises flavivirus having a phenotype in which the viral genome is modified by the introduction of a mutation, singly or in combination, taken from the group consisting of the mutations of Table 37, wherein said mutation is charge-cluster-to-alanine mutations at amino acids 2687 and 2688 of the NS5 gene, where amino acid position is given for the polyprotein of dengue virus type 4 200, 201.

2. **(Original)** The flavivirus of claim 1, further comprising the $\Delta 30$ mutation.

3. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a dengue virus type 1.

4. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a dengue virus type 2.

5. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a dengue virus type 3.

6. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a dengue virus type 4.

7. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a chimeric virus.

8. **(Original)** The chimeric virus of claim 7 having a dengue 1 backbone.

9. **(Original)** The chimeric virus of claim 7 having a dengue 2 backbone.

10. **(Original)** The chimeric virus of claim 7 having a dengue 3 backbone.

11. **(Original)** The chimeric virus of claim 7 having a dengue 4 backbone.

12. **(Original)** The flavivirus of claim 1, wherein the phenotype is temperature sensitivity in Vero cells or the human liver cell line HuH-7.

13. **(Canceled)**

14. **(Canceled)**

15. **(Canceled)**

16. **(Currently amended)** A pharmaceutical composition comprising a pharmacologically acceptable vehicle and a flavivirus according to any of claims 1-12 ~~1-15~~.

17.-32. **(Canceled)**